Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
- 5 August 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (10), 2444-2452
- https://doi.org/10.2337/dc20-0267
Abstract
OBJECTIVE Reports of amputations associated with sodium–glucose cotransporter 2 (SGLT2) inhibitors have been inconsistent. We aimed to compare the risk of below-knee amputation with SGLT2 inhibitors versus dipeptidyl peptidase 4 (DPP-4) inhibitors among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This multicenter observational study used administrative health care databases from seven Canadian provinces and the U.K. Incident SGLT2 inhibitor users were matched to DPP-4 inhibitor users using a prevalent new-user design and time-conditional propensity scores. Cox proportional hazards models were used to estimate site-specific adjusted hazard ratios (HR) and corresponding 95% CIs of incident below-knee amputation for SGLT2 inhibitor versus DPP-4 inhibitor users. Random effects meta-analyses were used to pool the site-specific results. RESULTS The study cohort included 207,817 incident SGLT2 inhibitor users matched to 207,817 DPP-4 inhibitor users. During a mean exposed follow-up time of 11 months, the amputation rate was 1.3 per 1,000 person-years among SGLT2 inhibitor users and 1.5 per 1,000 person-years among DPP-4 inhibitor users. The adjusted HR of below-knee amputations associated with SGLT2 inhibitor use compared with DPP-4 inhibitor use was 0.88 (95% CI 0.71–1.09). Similar results were obtained in stratified analyses by specific SGLT2 inhibitor molecule. CONCLUSIONS In this large multicenter observational study, there was no association between SGLT2 inhibitor use and incident below-knee amputations among patients with type 2 diabetes compared with DPP-4 inhibitor use. While these findings provide some reassurance, studies with a longer duration of follow-up are needed to assess potential long-term effects.Funding Information
- Canadian Institutes of Health Research (DSE-146021)
This publication has 29 references indexed in Scilit:
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic PatientsThe American Journal of Medicine, 2016
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scoresPharmacoepidemiology and Drug Safety, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Data Resource Profile: Clinical Practice Research Datalink (CPRD)International Journal of Epidemiology, 2015
- Validity of the General Practice Research DatabasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Increased Risk of Lower-Extremity Amputation Among Caucasian Diabetic Patients on DialysisDiabetes Care, 2001
- Use of the UK General Practice Research Database for pharmacoepidemiologyBritish Journal of Clinical Pharmacology, 1998
- Limitations and strengths of spontaneous reports dataClinical Therapeutics, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986